Dr Powles on the Function of the CREST Study in Future Medical Trial Design in BCG-Naive NMIBC

“We’ve tested [sasanlimab] in [NMIBC] in combination with BCG, [and] it showed a reduction in the risk of event-free survival with a hazard ratio of 0.68.”

Thomas Powles, MBBS, MRCP, MD, a professor of genitourinary oncology and the director of the Barts Cancer Centre at St. Bartholomew’s Hospital, highlighted how the section 3 CREST examine (NCT04165317)—evaluating the mixture of sasanlimab and BCG in sufferers with BCG-naive, high-risk, non–muscle-invasive bladder most cancers (NMIBC)—might additional inform scientific trial designs in NMIBC.

Patients on the trial had BCG-naive, high-risk, T1 or high-grade Ta NMIBC with or with out carcinoma in situ, and had not beforehand acquired PD-1, PD-L1, PD-L2, or CTLA-4 inhibitors or immunostimulatory brokers. Patients (n = 1055) have been randomly assigned 1:1:1 to obtain sasanlimab plus BCG induction and upkeep (arm A), sasanlimab plus BCG induction (arm B), or BCG induction plus upkeep (arm C).

The novel subcutaneous PD-1 inhibitor sasanlimab has proven scientific exercise in urothelial most cancers and has been additional investigated within the NMIBC paradigm together with BCG, Powles started. In the intent-to-treat inhabitants within the CREST trial, the event-free survival charges have been 84.7% and 82.1% at 24 and 36 months, respectively, within the sasanlimab plus BCG arm (n = 352) in contrast with 79.9% and 74.8%, respectively, within the BCG induction plus upkeep arm (n = 351; stratified HR, 0.68; 95% CI, 0.49-0.94; 1-sided P = .0095).

Based on this analysis, investigators have tried to find out acceptable subgroups of sufferers who would greatest profit from the sasanlimab mixture, Powles continued. Although there’s a small enchancment with the addition of sasanlimab to BCG induction plus upkeep, there’s nonetheless extra work to be accomplished, he added. The agent has proven exercise in different populations of sufferers; nonetheless, whether or not that exercise may be related to the PD-1 biomarker stays to be seen, he emphasised. There remains to be work to do, which has been evident by way of different research, together with the section 3 POTOMAC trial (NCT03528694), which is evaluating durvalumab (Imfinzi) plus BCG for the remedy of sufferers with high-risk, BCG-naive NMIBC, Powles concluded.